Trial Profile
Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Haematological malignancies; Mantle-cell lymphoma; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors BioMarin Pharmaceutical; Pfizer
- 06 Sep 2019 Results of population pharmacokinetics of talazoparib in patients with advanced cancer published in the Journal of Clinical Pharmacology
- 21 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 15 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.